Table 5.
Disease-free survival analyses according to preoperative PDW in 495 patients with ESCC.
| Variables | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | |
| PDW (≥13.4 vs. <13.4) | 2.302 | 1.567–3.383 | <0.001 | 2.562 | 1.733–3.786 | <0.001 |
| Sex (male vs.female) | 1.545 | 0.830–2.878 | 0.170 | |||
| Age (>60 vs. ≤60) | 0.881 | 0.610–1.273 | 0.501 | |||
| Depth of tumor | ||||||
| T1a–1b | 0.838 | 0.435–1.614 | 0.597 | |||
| T2 | 0.601 | 0.357–1.011 | 0.055 | |||
| T3 | 1.000 | |||||
| Lymph node metastasis | ||||||
| N0 | 0.160 | 0.084–0.303 | <0.001 | 0.205 | 0.074–0.569 | 0.002 |
| N1 | 0.266 | 0.141–0.500 | <0.001 | 0.265 | 0.136–0.515 | <0.001 |
| N2 | 0.471 | 0.243–0.915 | 0.026 | 0.424 | 0.217–0.827 | 0.012 |
| N3 | 1.000 | 1.000 | ||||
| Pathological stage | ||||||
| 1a–1b | 0.376 | 0.203–0.694 | 0.002 | 1.039 | 0.363–2.975 | 0.943 |
| 2a–2b | 0.511 | 0.337–0.775 | 0.002 | 1.082 | 0.517–2.261 | 0.835 |
| 3a–3c | 1.000 | 1.000 | ||||
| Vessel invasive (absence vs. presence) | 1.376 | 0.927–2.043 | 0.114 | |||
| Nerve infiltration (absence vs. presence) | 1.640 | 1.131–2.380 | 0.009 | 1.424 | 0.960–2.113 | 0.079 |
| Treatment regimen | ||||||
| S | 0.496 | 0.280–0.878 | 0.016 | 0.551 | 0.306–0.993 | 0.047 |
| S plus postoperative C | 1.344 | 0.748–2.416 | 0.323 | 1.304 | 0.719–2.364 | 0.382 |
| S plus postoperative CRT | 1.000 | |||||
| Hospital time (days) (>14 vs. ≤14) | 1.214 | 0.773–1.905 | 0.399 | |||
| Platelet | 0.998 | 0.995–1.001 | 0.285 | |||
| Albumin | 0.969 | 0.922–1.019 | 0.217 | |||
| RDW | 1.149 | 0.931–1.418 | 0.195 | |||
| Aspartate transaminase | 0.997 | 0.975–1.019 | 0.791 | |||
| Fibrinogen | 0.931 | 0.748–1.159 | 0.524 | |||
| Hemoglobin | 0.962 | 0.847–1.091 | 0.545 | |||
Abbreviations: S, surgery; C, chemotherapy; CRT, chemoradiotherapy; PDW, platelet distribution width; RDW, red cell distribution width.